Human multidrug resistance-related protein 2 (MRP2, encoded by ABCC2) is involved in the transport of anionic drugs such as methotrexate (MTX). We prospectively investigated the influence of four common ABCC2 genetic variants (rs717620, rs2273697, rs8187694 and rs8187710) on MTX pharmacokinetics parameters. MTX concentrations were monitored in 50 patients with lymphoid malignancy (27 males; mean age: 53±17 years) receiving high-dose MTX (5.13±1.88 g m À 2 in a 4-h perfusion). The population pharmacokinetics modelling showed that ABCC2 À 24T allele (rs717620) had a combined influence on both MTX elimination and distribution. The MTX clearance and distribution volume were significantly higher in carriers of at least one copy of the À 24T allele as compared with noncarriers: 8.6±2.2 vs 6.7± 2.5 l h À 1 , Po0.01 and 30.7±7.7 vs 22.1±8.8 l, Po0.001, respectively. Consequently, À 24T allele carriers were more prone to reach MTX nontoxic levels, 48 h after administration.
INTRODUCTION
Methotrexate (MTX) is an analog of aminopterine, a folic acid antagonist, used as an anticancer agent since 1948. High-dose MTX regimen (HD-MTX; 1-8 g m À 2 intravenous (i.v.) injection) with folate rescue is a cornerstone in the treatment of lymphoid haemopathies (including Burkitt's lymphoma, large-cell lymphoma and acute lymphoblastic leukaemia [1] [2] [3] ), as it fights against potential neuromeningeal localization.
There is a well-established relationship between MTX kinetics, its efficacy and toxicity. Some studies have suggested that the plasma maximal concentration (C max ) and the area under the timeconcentration curve are major prognosis factors in histological response and disease-free survival. 4 A steady-state concentration 416 mmol l À 1 has been associated with a reduced risk of relapse. 5 On the other hand, increased plasma concentrations are associated with a higher risk of adverse drug effects.
There is a large variability in MTX kinetics supporting a strict monitoring of plasma concentrations after administration, and resulting in prolonged hospitalizations in some patients. Factors contributing to this variability are the following: age, gender, renal function evaluated by the markers of glomerular filtration, insufficient hydration and concomitant treatments influencing the renal transporters. [6] [7] [8] However, this variability remains largely unexplained, particularly in patients with normal renal function and sufficient hydration.
Recent evidence has suggested that the ATP-binding cassette transporter ABCC2 (or MRP2 for multidrug-resistance-related protein 2) is involved in the active transport of MTX through the plasma membrane. 9, 10 ABCC2 is expressed in the canalicular side of human hepatocytes, in the brush border membrane of renal proximal tubules in kidneys and at the luminal surface of endothelial cells of the brain. 11 Several genetic variants have been found in the ABCC2 gene. Some of these appear to be associated with MRP2 loss of function, maximally leading to the DubinJohnson syndrome, a rare form of conjugated hyperbilirubinemia with characteristic abnormalities of urinary coproporphyrin isomer distribution. 12 In a previous study, we have shown that a mutation in ABCC2 (substitution of arginine to glycine at position 412) led to the inactivation of MRP2, and was associated in human with an impaired MTX elimination, thus indicating a central role for MRP2 in MTX pharmacokinetics. 13 However, such rare and private mutations are unlikely to explain the wide interindividual variability observed in MTX elimination. Different ABCC2 single-nucleotide polymorphisms (SNPs) have been reported. 14, 15 We hypothesized that more frequent and less penetrant ABCC2 SNPs may contribute to interindividual variability in the MTX pharmacokinetics.
The objectives of our study were to develop a population pharmacokinetic model of HDMTX in order to investigate the effect of four ABCC2 SNPs and of different physiopathological and demographic factors on the MTX pharmacokinetics.
MATERIALS AND METHODS

Patient and treatment
This study included patients with large-cell lymphoma, Burkitt's lymphoma and acute lymphoblastic leukaemia who were hospitalized between October 2003 and July 2005 in the haematology and neurology departments of Pitié -Salpé triè re Hospital to receive high-dose MTX. The study was approved by the Ethics Committee of Pitié -Salpê triè re Hospital, Paris, France, according to the requirement of the French law on clinical research.
Fifty patients were enrolled. A total number of 136 courses (1-6 per patient) were available for analysis. Patients presenting any contraindication to MTX were excluded. Treatments known to modify the MTX pharmacokinetics (that is, salicylates, cisplatin, barbiturates, phenytoin) were contraindicated. Informed consent was obtained from all patients. Each patient was included in this study only at one MTX course and then the data for other courses were collected from the patient files. No extra tests or blood sampling were done during these courses. The total number of courses was determined by the physician.
MTX administration
Urine alkalinisation and i.v. hydration were performed by administration of i.v. 1.4% sodium bicarbonate and 5% glucose, 2 g l À 1 KCl 4 g l À 1 NaCl, 30-40 ml kg À 1 per 24 h) from the start of the infusion up to 72 h. The dose of MTX (from 1 to 8 g m À 2 ) was administered as a 1-6-h i.v. infusion. Folinic acid 50 mg i.v. adjusted to MTX concentrations according to the protocol guidelines was given at 24 h after the start of MTX infusion and repeated every 6 h until MTX concentration is o0.03 mmol l À 1 .
Measurement of MTX concentrations
Several blood samples were collected from all patients at the end of infusion and 8-12 h, 24 h, 48 h after drug administration, and eventual follow-up plasma-level determination at 72 h or more if the MTX was not yet eliminated (MTX concentration40.03 mmol l À 1 ). The first two supplementary blood samples were obtained only during the duration of patient's participation (only one course).
MTX concentrations were determined by EMIT (enzymatic multiplied immunoassay technique, Siemens, Germany), with a centrifugal COBAS analyzer. The limit of quantification was of 0.03 mmol l À 1 . Quality control assessments were done during the whole study period. Values below or at (limit of quantification) were fixed to 0.015 mmol l À 1 (limit of quantification/2).
Genotyping
Genomic DNA was extracted from peripheral-blood leukocytes using standard procedures (Puregene DNA isolation kit, Merck Eurolab, Lyon, France). All subjects were genotyped for the À 24 C4T SNP (rs717620) in All known ABCC2 SNPs were selected if having minor allelic frequencies 45% (as referenced in the Hapmap CEU population), and leading to amino-acid substitution (three non-synonymous SNPs) or affecting ABCC2 transcriptional regulation ( À 24 C4T SNP).
Population PK model Data were analysed using the nonlinear mixed effect modelling software program NONMEM (version 7.2) 16 with the DIGITAL FORTRAN compiler (Nashua, NH, USA). The first-order conditional estimate method was used for the parameters estimation. After investigation of two-and threecompartment models the time course of MTX concentrations was ascribed to a linear three-compartment model with elimination from the central compartment. The three-compartment model was chosen on the basis of previous knowledge, parameters estimations precision and visual fits.
The model parameters were the volume of the central compartment V1, the total-body clearance CL, the inter-compartment clearances Q2 and Q3, and the volumes of the peripheral compartment V2 and V3.
Several error models were investigated (that is, proportional, exponential and additive error models) to describe intersubject variability (ISV) and residual variabilities. The random effect was modelled with unstructured (block) covariance. The inter-occasion variability was also considered.
The influence of continuous covariates was modelled according to the following equation, using CL for example:
where TV (CL) is the typical value of CL for a patient with the median covariate value and y age is the estimated influential factor for age (it can be a positive or a negative, effect). Such covariates included bodyweight, height, body surface area, age, serum creatinine, creatinine clearance (calculated according to Cockcroft and Gault formula), ASAT, ALAT, Gamma GT, total bilirubin, alkaline phosphatase and proteinemia.
Categorical covariates including gender and genotyping were tested according to the following equations using a positive effect for example:
where 1 or 2 denote male or female gender.
Or in the case of a decreasing effect,
Covariates were selected and retained in the population model if (i) their effect was biologically plausible, (ii) they produced a minimum reduction of 4 units of the objective function value (OFV) and (iii) they produced a reduction in the variability of the pharmacokinetic parameter, assessed by the associated intersubject variability (ISV).
Then, all covariates identified as potentially relevant where included in a full model. The final model was then obtained by dropping all nonsignificant covariates that is, producing a reduction of o8 units of the OFV. Graphical plots were used to assess the quality of fits.
For evaluation of the goodness of fit, the following graphs were compared: observed concentrations vs predictions (DV-PRED), observed concentrations vs individual predictions (DV-IPRE), normalized predictive distribution errors vs time (npde-TIME), normalised predictive distribution errors vs predictions (npde-PRED) and observed concentrations vs time with 90% interval of prediction (visual predictive check), as well as the corresponding graphs issued from the POSTHOC estimation step. Diagnostic graphics and distribution statistics were obtained using the R program. ABCC2 and high-dose methotrexate pharmacokinetics N Simon et al
The accuracy and robustness of the final population model were then assessed using a bootstrap method. 18 From the original data set of patients, 1000 bootstraps were drawn with resampling. For each of the 1000 bootstrap sets, the population parameters were estimated. Then, the mean and s.d. of these 1000 estimates were compared with those obtained in the original population set. The model was considered validated if no significant differences were observed.
Statistical analyses
Analyses were done with SAS (version 9.1, Cary, NC, USA). Continuous variables were expressed as mean±s.d. and categorical variables as frequencies and percentages. Continuous variables were compared with Mann-Whitney rank-sum test. The Kruskall-Wallis test was used for multiple comparisons across genotypes. Categorical variables were compared by means of the w 2 test or Fisher's exact test. Linear regression analyses were performed to evaluate the association between the tested genotypes and PK parameters. All P values are two-sided and a value of Po0.05 was considered significant.
RESULTS
Patient characteristics
Main characteristics of the fifty enrolled patients are presented in Table 1 . Forty-five patients presented with large-cell lymphoma, three patients with Burkitt's lymphoma and two patients with acute lymphoblastic leukaemia. The mean ± s.d. MTX dose was 5.1±1.9 g m À 2 and was administered in a 3.9±0.9 h infusion. Table 2 shows genotype and allele frequencies, as identified in the study population. The 3563T4A (Val1188Glu, rs8187694) in exon ). The number of samples was 2-11 samples per course. Several patients did not reach the thresholds of 0.03 mmol l À 1 before 72 h, and the maximal monitoring time was 291 h.
The MTX time-concentration courses were best described by linear three-compartment model with first-order elimination from the central compartment. Intersubject variability could be estimated for CL, and V1, and were best described using an exponential error model. The addition of covariance term between CL and V1 decreased significantly the OFV and resulted in improved precision of the parameter estimates. The residual variability was best described by an exponential error model.
Observation of the plots of posteriori Bayesian estimates of pharmacokinetic parameters in individual patients indicated that markers of lower renal function were associated with decreased CL.
Univariate analysis of the demographic characteristics performed by forward inclusion into the base model confirmed that CL was significantly influenced by creatinine clearance level (correlation coefficient of r ¼ 0.51, Po0.0002). Incorporation of creatinine clearance to predict MTX CL/F led to a decrease in the intersubject variability (ISV) on the clearance by 5% and a decrease in the objective function by 33 points (Po0.001).
We then analysed the potential influence of ABCC2 SNPs on MTX pharmacokinetic parameters. We found that the À 24C4T SNP in 5 0 -untranslated region had a significant effect on both CL and V1 with a decrease of OFV by 30 points. The ISV of CL was reduced from 38 to 32%, whereas the ISV of V1 falls from 70 to 38%. The MTX CL was significantly higher in carriers of at least one copy of the rare À 24T allele as compared with noncarriers: 8.6± 2.2 vs 6.7± 2.5 l h À 1 , Po0.01 (Figure 2a) . We also found that carriers of at least one copy of the À 24T allele had significantly higher V1 values than noncarriers: 30.7±7.7 vs 22.1±8.8 l, Po0.001 (Figure 2b) . In multivariable linear regression analyses containing the tested ABCC2 polymorphisms, the À 24T allele was the only predictor of MTX clearance and volume of distribution (P ¼ 0.01 and P ¼ 0.002, respectively). None of the other investigated ABCC2 SNPs had a significant influence on MTX pharmacokinetic parameters. Adjustment for nongenetic potential confounders (gender, age, weight, MTX dose, creatinine clearance) did not alter this result.
In line with a faster elimination rate and a higher distribution volume, mean plasma MTX concentration at H48 was significantly lower in patients carrying at least one À 24T allele as compared with noncarriers (0.13 ± 0.12 mmol vs 0.29 ± 0.16 mmol l À 1 , Po0.003). Eleven of the 16 (68.75%) patients carrying the rare À 24T allele but only 9/34 (26.5%) of patients with the wild-type À 24C allele presented with MTX concentrations below the toxic threshold (o0.1 mmol l À 1 ) at H48 (Po0.005). None of the other SNPs had a significant influence on MTX PK parameters and none of the other covariates had any significant effect on Q2, V2, Q3 or V3. The final model was subjected to a bootstrap analysis (1000 replicates) and incorporates creatinine clearance and ABCC2 À 24C4T on CL and ABCC2 À 24C4T on V1 decreasing the objective function by 45 points. Table 3 summarizes the results presented as means and 95% confidence intervals (2.5th and 97.5th percentiles). Bootstrap means and mean parameters from the original data set were reasonably similar and indicated acceptable precision. The correlation between predicted and observed MTX concentration was ABCC2 and high-dose methotrexate pharmacokinetics N Simon et al 0.87, and the correlation between individual predicted and observed MTX concentration was 0.94 ( Figure 3 ). Using the individual MTX PK parameters, we were able to perform further computations to estimate the time to reach the MTX toxic threshold after starting administration. We found that this time will be reached at 53.4±16.1 h in carriers of the À 24T allele vs 61.4 ± 14.6 h in patients with the À 24CC genotype (P ¼ 0.03).
DISCUSSION
The present study showed that a common polymorphism located in the 5 0 -untranslated region of ABCC2 is an independent predictor of HDMTX pharmacokinetics in patients with lymphoid malignancy. Population PK modeling allowed us to estimate that patients carrying the rare T allele not only had a B30% increase in MTX clearance but also an E40% increase in the centralcompartment volume, suggesting that ABCC2 is involved in both MTX elimination and distribution. Consequently, the delay to disappearance of MTX from the peripheral blood is significantly faster in carriers of the ABCC2 À 24T allele as compared with noncarriers.
This study expands upon previous observations that assessed the role of MRP2 in MTX kinetics. The involvement of MRP2 in MTX transport has been described in vitro by cell culture experiments and in vivo by altered pharmacokinetics in animal models with deficient MRP2. 9, 10 In a previous study, we have reported the case of a patient with the Dubin-Johnson syndrome (DJS) that 13 DJS is a rare genetic recessive disorder characterised by conjugated hyperbilirubinemia and caused by a deficient MRP2 expression in canalicular membranes of hepatocytes. 12 Many ABCC2 mutations causing DJS have been reported. 19 The screening of our patient's DNA allowed us to discover a heterozygous missense mutation (1271A4G, 412 Arg4Gly) that was associated with a nonfunctional MRP2 protein and in impaired MTX transport in in vitro experiments. 13 In the present study, we now report that not only rare mutations but also a common ABCC2 polymorphism is associated with significant changes in MTX pharmacokinetics. This polymorphism is located in the 5 0 -untranslated region of the gene, a region associated with transcriptional regulation of MRP2 protein expression. 20 This variant occurs with a relatively high allelic frequency (that is, 16% in caucasians according to Genbank database) and has been previously associated with enhanced enterohepatic circulation of mycophenolic acid, 21 as well as with MTX plasma concentrations in pediatric patients who received MTX in a 24-h perfusion. 22 In this later study, 22 carriers of the À 24T allele had an opposite effect as the one observed in our study with higher MTX plasma concentrations and lower clearance. There was, however, a significant interaction with gender, the genetic variant effect being only observed in females. We did not observe such an influence in our adult population that could also be related to the different scheme of MTX administration or to the elder age of patients.
The mechanism underlying the association between the ABCC2 À 24T allele and MTX pharmacokinetics remains unclear. MRP2 is expressed on the canalicular membrane of hepatocytes and on the apical membrane of renal proximal tubules, suggesting an involvement in the excretion of xenobiotics out of the body. Consistently, we found a significant influence of ABCC2 polymorphism on MTX excretion rate. However, we were also able to find a significant influence of ABCC2 polymorphism on the MTX volume of distribution. MRP2 is also expressed in internal organs mainly in the blood-brain barrier. 23 Because of its ability to cross the blood-brain barrier, MTX is the most widely used hydrophilic chemotherapeutic agent in the central nervous system lymphoma, but the delivery to the brain remains limited. A negative influence of À 24T on the ABCC2 promoter activity has been found in vitro with, however, a limited amplitude. 24, 25 Some studies have failed to find a change in MRP2 expression in vivo in different tissues, 26, 27 raising concerns on the direct influence of the À 24T allele on the expression level of MRP2. Intriguingly, Ufer et al. 26 have a found a significant association between the ABCC2 À 24C4T polymorphism and ABCB1 expression in the brain. 26 MTX is supposed to be carried out by several transporters in addition to MRP2. Whether the ABCC2 À 24T allele indicates a functional change in the MTX transport system that extends beyond changes in MRP2 activity should deserve further investigations. Our results emphasize that changes in drug transport are likely to affect several pharmacokinetic steps. A recent study has shown that inhibition of MRP2 affects the oral availability of MTX. 28 This could not have been observed in our study where MTX was administered intravenously, but this observation is in line with MRP2 expression in the small intestine.
The present population pharmacokinetics analysis confirmed that a three-compartment model was the most accurate for describing HDMTX data. The clearance and central volume of distribution typical values were similar to those already described. 29, 30 Several covariates were previously identified for explaining interindividual variability, that is, Odoul et al. 31 reported that clearance and volume of distribution were increased with weight and age and Aumente et al. 32 showed that the children aged p10 years had a higher clearance than the children aged 410 years.
The high intersubject variability (ISV) and the narrow therapeutic index of MTX made the therapeutic monitoring a requirement for this anticancer agent. For this reason, every factor that could affect MTX concentrations, such as a drug combination, has to be managed cautiously. This study shows that 10% of ISV of clearance and 33% of ISV of the central volume of distribution could be explained by a polymorphism in the region of ABCC2. This strongly suggests that investigating this genotype at the beginning of treatment could help clinicians in monitoring MTX dosage. Meanwhile, further studies have to be performed in order to evaluate if genotyping the À 24C4T in 5 0 -untranslated region of the ABCC2 gene might influence clinical outcome in patients with lymphoid haemopathy.
